192 related articles for article (PubMed ID: 34023506)
1. Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles.
Kakiuchi Y; Kuroda S; Kanaya N; Kumon K; Tsumura T; Hashimoto M; Yagi C; Sugimoto R; Hamada Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Urata Y; Fujiwara T
Mol Ther; 2021 Oct; 29(10):2920-2930. PubMed ID: 34023506
[TBL] [Abstract][Full Text] [Related]
2. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
3. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
[TBL] [Abstract][Full Text] [Related]
4. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
6. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
7. Heterologous and cross-species tropism of cancer-derived extracellular vesicles.
Garofalo M; Villa A; Crescenti D; Marzagalli M; Kuryk L; Limonta P; Mazzaferro V; Ciana P
Theranostics; 2019; 9(19):5681-5693. PubMed ID: 31534511
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Yokoyama T; Iwado E; Kondo Y; Aoki H; Hayashi Y; Georgescu MM; Sawaya R; Hess KR; Mills GB; Kawamura H; Hashimoto Y; Urata Y; Fujiwara T; Kondo S
Gene Ther; 2008 Sep; 15(17):1233-9. PubMed ID: 18580968
[TBL] [Abstract][Full Text] [Related]
10. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
12. Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial.
Heo J; Liang JD; Kim CW; Woo HY; Shih IL; Su TH; Lin ZZ; Yoo SY; Chang S; Urata Y; Chen PJ
Mol Ther; 2023 Jul; 31(7):2077-2088. PubMed ID: 37060176
[TBL] [Abstract][Full Text] [Related]
13. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
14. Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer.
Nakajima O; Ichimaru D; Urata Y; Fujiwara T; Horibe T; Kohno M; Kawakami K
Oncol Rep; 2009 Nov; 22(5):1039-43. PubMed ID: 19787218
[TBL] [Abstract][Full Text] [Related]
15. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy.
Fujiwara T; Kagawa S; Kishimoto H; Endo Y; Hioki M; Ikeda Y; Sakai R; Urata Y; Tanaka N; Fujiwara T
Int J Cancer; 2006 Jul; 119(2):432-40. PubMed ID: 16477640
[TBL] [Abstract][Full Text] [Related]
17. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
[TBL] [Abstract][Full Text] [Related]
19. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
